NCT06288893View on ClinicalTrials.gov

SHEN211 Tablets for the Treatment of Mild and Moderate Novel Corona Virus Infections (COVID-19)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

August 1, 2024

Study Completion Date

January 1, 2025

Conditions
COVID-19
Interventions
DRUG

SHEN211 Tablets

SHEN211 tablets, participants will receive 330 mg (3 tablets) QD (once a day) on Day 1 and 110 mg (1 tablet) SHEN211 tablets QD orally on Days 2-5.

PROCEDURE

Placebo for SHEN211 Tablets

Placebo tablets, participants will receive 3 tablets QD (once daily) on Day 1 and 1 tablet QD orally on Days 2-5

Trial Locations (1)

518112

Shenzhen Third People 's Hospital, Shenzhen

All Listed Sponsors
lead

JKT Biopharma Co., Ltd.

INDUSTRY